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pathologies, such as lung nodules and lung carcinoma,
there may be some diagnostic and therapeutic difficulties.
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Brief Clinical ReportsPotential for benefits of aprotinin use to outweigh risks in patients
undergoing the Ross procedure
Stephen Arthur Barnett, MBBS, FRACS, Matthew Liava’a, MBBS, and Peter D. Skillington, MBBS,
FRACS, Melbourne, AustraliaRecent reports1-3 of adverse events related to the use of
aprotinin during complex cardiac surgery and the sudden
suspension of the BART (Blood conservation using antifi-
brinolytics: A randomized trial in a cardiac surgery popula-
tion) trial because of excess mortality in the treatment arm4
highlight the risks of death, acute renal failure, and acute cor-
onary thrombosis during the perioperative period after treat-
ment with this drug. Our concern is that the very real benefits
of the drug in terms of reductions in bleeding, need to return
to the operating room, and rate of transfusion of blood and
blood products2 may be overlooked as a result of the surgical
community’s admirable goal to ‘‘first do no harm.’’ More
specifically, we suspect that there may be a subgroup of
younger patients undergoing complex cardiac surgical pro-
cedures who could derive many of the previously accepted
benefits with a low risk of the recently highlighted adverse
events attributed to the drug.
CLINICAL SUMMARY
Between October 1992 and November 2007, a total of
250 consecutive patients underwent the Ross procedure un-
der the care of a single surgeon (P.D.S.).5 Aprotinin was ad-
ministered routinely to all patients, according to the full
Hammersmith protocol.6 Mean age was 39.5 years (range
15–62 years). Mean total bypass time was 195 minutes,
and mean cumulative crossclamp time was 165 minutes.
Bleeding necessitating return to the operating room oc-
curred in 7 patients (2.8%). Transfusion of blood or blood
products was necessary in 75 patients (30%).
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ciated with the administration of aprotinin, there were no
in-hospital deaths, and acute renal impairment (defined as
a doubling of preoperative creatinine level) occurred in
only 4 patients (1.6%). No patients required hemofiltra-
tion. There were no acute thromboses of any coronary
artery, although 2 patients (0.8%) did require early revi-
sion (1 during the initial time in the operating room and
1 after return to the operating room) as a result of kink-
ing of a coronary artery (this complication was encoun-
tered solely in the early period of the series and has
since been universally prevented by a modification of
technique).
DISCUSSION
It is our impression that young, fit patients undergoing
complex procedures, such as the Ross procedure or adult
congenital cardiac surgery, involving numerous suture lines
and prolonged bypass times can benefit from the use of apro-
tinin. Further, in this select group of patients, who often have
only a small burden of atherosclerotic coronary and renovas-
cular disease, the possible thrombotic complications of apro-
tinin—namely acute coronary occlusion, acute renal failure,
and subsequent in-hospital mortality—may be uncommon.
The well-accepted benefits of reduced blood loss and the
low rates of adverse events in this select group of patients
may therefore tip the balance in favor of the ongoing use
of this drug.
More work is needed. A randomized trial at our institution
addressing whether withholding aprotinin from patients
undergoing the Ross procedure would result in reduced in-
hospital mortality is impossible, however, because our start-
ing death rate is 0%. Similarly, withholding aprotinin in the
hope of discerning a reduction in acute renal failure from our
starting level of 1.6% would require many thousands of
patients.Cardiovascular Surgery c Volume 138, Number 1 233
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2007;133:1547-52.Left main compression syndrome by
aneurysm caused by medial necrosis
bicuspid pulmonary valve
Daniel Jodocy, MD,a Guy J. Friedrich, MD,a Johannes O
Guenther Laufer, MD,c Otmar Pachinger, MD, FECTS,a
Gudrun M. Feuchtner, MD,b Innsbruck, Austria
A 71-year-old man with episodes of dyspnea presented
with stress-induced anterior myocardial ischemia on myo-
cardial single photon emission computed tomography. He
was referred for invasive angiography, which revealed
a left main coronary artery ostial catheter pressure decrease
and an atypical configuration of the left main stem
(Figure 1, A).
CLINICAL SUMMARY
Cardiac electrocardiogram-gated 64-slice computed
tomography was performed, showing a giant pulmonary an-
eurysm (6 cm in diameter) (Figure 1, B-D) that significantly
(>50%) compressed the left main coronary artery during
both systole and diastole. A tender bicuspid pulmonary
valve without degenerative lesion (Figure 1,D, inlay bottom
left) was found.
Pulmonary valve stenosis, pulmonary artery hyperten-
sion, and any congenital heart disease, such as atrial or ven-
tricular septal defects, were excluded by transesophageal
echocardiography. The patient underwent cardiac surgery
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under median sternotomy and cardiopulmonary bypass, in-
cluding double left internal thoracic artery/left anterior de-
scending and aortocoronary saphenous vein grafting to the
circumflex artery and surgical reconstruction of the pulmo-
nary artery aneurysm. Pathohistology of the pulmonary
artery demonstrated degenerative mucoid medial necrosis
Erdheim-Gsell (Figure 2). The patient was discharged on
the seventh postoperative day. A 3-month follow-up was
uneventful.
DISCUSSION
‘‘Left main compression syndrome’’1 is a rare phenome-
non that is defined as a functional compression of the left
main coronary artery, for example, between a dilated pulmo-
nary artery more than 4 cm in diameter2 and the aortic root,
or an aneurysm of the sinus of Valsalva.3
Pulmonary artery aneurysms are most commonly associ-
ated with congential heart disease, such as persistent ductus
Botalli, atrial or ventricular septal defects, or tetralogy of
Fallot,4 or develop after pulmonary valve stenosis. Idio-
pathic pulmonary artery aneurysms are rare,4,5 with an esti-
mated incidence of 1 in 13,696 in an autopsy series.5 Similar
to ascending aortic aneurysm, idiopathic pulmonary aneu-
rysm may be associated with the presence of congenital bi-
cuspid pulmonary valves,6 a rare entity7 in the absence of
congenital heart disease. However, in contrast with our
case, the study by Sughimoto and colleagues6 did not find
medial necrosis.
In our patient, cardiac electrocardiogram-gated multislice
computed tomography was the key to clarify the atypical
presentation of left main stenosis on invasive coronary
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